BACKGROUND: Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell activity. Due to the important role that GITR plays in regulating immune functions, agonistic stimulation of GITR is a promising therapeutic concept. Multiple strategies to induce GITR signaling have been investigated. The limited clinical efficacy of antibody-based GITR agonists results from structural and functional characteristics of antibodies that are unsuitable for stimulating the well-defined trimeric members of the TNFRSF. METHODS: To overcome limitations of antibody-based TNFRSF agonists, we have developed HERA-GITRL, a fully human hexavalent TNF receptor agonist (HERA) targeting GITR and mimicking the natural signaling concept. HERA-GITRL is composed of a trivalent but single-chain GITRL-receptor-binding-domain (scGITRL-RBD) unit fused to an IgG1 derived silenced Fc-domain serving as dimerization scaffold. A specific mouse surrogate, mmHERA-GITRL, was also generated to examine in vivo activity in respective mouse tumor models. RESULTS: For functional characterization of HERA-GITRL in vitro, human immune cells were isolated from healthy-donor blood and stimulated with anti-CD3 antibody in the presence of HERA-GITRL. Consistently, HERA-GITRL increased the activity of T cells, including proliferation and differentiation, even in the presence of regulatory T cells. In line with these findings, mmHERA-GITRL enhanced antigen-specific clonal expansion of both CD4+ (OT-II) and CD8+ (OT-I) T cells in vivo while having no effect on non-specific T cells. In addition, mmHERA-GITRL showed single-agent anti-tumor activity in two subcutaneous syngeneic colon cancer models (CT26wt and MC38-CEA). Importantly, this activity is independent of its FcγR-binding functionality, as both mmHERA-GITRL with a functional Fc- and a silenced Fc-domain showed similar tumor growth inhibition. Finally, in a direct in vitro comparison to a bivalent clinical benchmark anti-GITR antibody and a trivalent GITRL, only the hexavalent HERA-GITRL showed full biological activity independent of additional crosslinking. CONCLUSION: In this manuscript, we describe the development of HERA-GITRL, a true GITR agonist with a clearly defined mechanism of action. By clustering six receptor chains in a spatially well-defined manner, HERA-GITRL induces potent agonistic activity without being dependent on additional FcγR-mediated crosslinking.

Present address Biotest AG Dreieich Germany

Present address SOTIO Prague Czech Republic

Research and Development Apogenix AG Im Neuenheimer Feld 584 69120 Heidelberg Germany

Zobrazit více v PubMed

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi: 10.1126/science.aaa8172. PubMed DOI

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi: 10.1038/nri3405. PubMed DOI PMC

Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, et al. Agonists of co-stimulation in Cancer immunotherapy directed against Cd137, Ox40, Gitr, Cd27, Cd28, and Icos. Semin Oncol. 2015;42(4):640–655. doi: 10.1053/j.seminoncol.2015.05.014. PubMed DOI

Watts TH. Tnf/Tnfr family members in Costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68. doi: 10.1146/annurev.immunol.23.021704.115839. PubMed DOI

Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (Tnf) and Tnf receptor family members in the mouse and human. J Biol Chem. 2006;281(20):13964–13971. doi: 10.1074/jbc.M601553200. PubMed DOI

Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, Moraca R, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A. 1997;94(12):6216–6221. doi: 10.1073/pnas.94.12.6216. PubMed DOI PMC

Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7. doi: 10.1186/2051-1426-2-7. PubMed DOI PMC

Riccardi C, Ronchetti S, Nocentini G. Glucocorticoid-induced Tnfr-related gene (Gitr) as a therapeutic target for immunotherapy. Expert Opin Ther Targets. 2018;22(9):783–797. doi: 10.1080/14728222.2018.1512588. PubMed DOI

Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in Cancer. Nat Rev Drug Discov. 2018;17(7):509–527. doi: 10.1038/nrd.2018.75. PubMed DOI

Wajant H. Principles of antibody-mediated Tnf receptor activation. Cell Death Differ. 2015;22(11):1727–1741. doi: 10.1038/cdd.2015.109. PubMed DOI PMC

Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of Cd27l, Cd40l, 41bbl, and glucocorticoid-induced Tnf receptor ligand. J Immunol. 2009;183(3):1851–1861. doi: 10.4049/jimmunol.0802597. PubMed DOI

Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, Malashkevich VN, Dilorenzo TP, Brenowitz M, et al. Assembly and structural properties of glucocorticoid-induced Tnf receptor ligand: implications for function. Proc Natl Acad Sci U S A. 2007;104(49):19452–19457. doi: 10.1073/pnas.0709264104. PubMed DOI PMC

Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, et al. Apg350 induces superior clustering of Trail receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther. 2013;12(12):2735–2747. doi: 10.1158/1535-7163.MCT-13-0323. PubMed DOI

Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, et al. A single-chain-based hexavalent Cd27 agonist enhances T cell activation and induces anti-tumor immunity. Front Oncol. 2018;8:387. doi: 10.3389/fonc.2018.00387. PubMed DOI PMC

Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Muller M, et al. The hexavalent Cd40 agonist Hera-Cd40l induces T-cell-mediated antitumor immune response through activation of antigen-presenting cells. J Immunother. 2018;41(9):385–398. PubMed

Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1994;1(4):327–339. doi: 10.1016/1074-7613(94)90084-1. PubMed DOI

Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012;188(9):4135–4140. doi: 10.4049/jimmunol.1102661. PubMed DOI PMC

Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating fc gamma receptors contribute to the antitumor activities of Immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685–1693. doi: 10.1084/jem.20130573. PubMed DOI PMC

Ryan JM, Wasser JS, Adler AJ, Vella AT. Enhancing the safety of antibody-based immunomodulatory Cancer therapy without compromising therapeutic benefit: can we have our cake and eat it too? Expert Opin Biol Ther. 2016;16(5):655–674. doi: 10.1517/14712598.2016.1152256. PubMed DOI PMC

Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-Ctla-4 and anti-Pd-1. Front Immunol. 2014;5:206. doi: 10.3389/fimmu.2014.00206. PubMed DOI PMC

June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of Cancer immunotherapy? Nat Med. 2017;23(5):540–547. doi: 10.1038/nm.4321. PubMed DOI

Nocentini G, Ronchetti S, Petrillo MG, Riccardi C. Pharmacological modulation of Gitrl/Gitr system: therapeutic perspectives. Br J Pharmacol. 2012;165(7):2089–2099. doi: 10.1111/j.1476-5381.2011.01753.x. PubMed DOI PMC

Li F, Ravetch JV. A general requirement for Fcgammariib co-engagement of agonistic anti-Tnfr antibodies. Cell Cycle. 2012;11(18):3343–3344. doi: 10.4161/cc.21842. PubMed DOI PMC

Li F, Ravetch JV. Antitumor activities of agonistic anti-Tnfr antibodies require differential Fcgammariib Coengagement in vivo. Proc Natl Acad Sci U S A. 2013;110(48):19501–19506. doi: 10.1073/pnas.1319502110. PubMed DOI PMC

Chattopadhyay K, Ramagopal UA, Brenowitz M, Nathenson SG, Almo SC. Evolution of Gitrl immune function: murine Gitrl exhibits unique structural and biochemical properties within the Tnf superfamily. Proc Natl Acad Sci U S A. 2008;105(2):635–640. doi: 10.1073/pnas.0710529105. PubMed DOI PMC

Zhou Z, Tone Y, Song X, Furuuchi K, Lear JD, Waldmann H, et al. Structural basis for ligand-mediated mouse Gitr activation. Proc Natl Acad Sci U S A. 2008;105(2):641–645. doi: 10.1073/pnas.0711206105. PubMed DOI PMC

Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, et al. Anaphylaxis caused by repetitive doses of a Gitr agonist monoclonal antibody in mice. Blood. 2014;123(14):2172–2180. doi: 10.1182/blood-2013-12-544742. PubMed DOI PMC

Belmar NA, Chan SW, Fox MI, Samayoa JA, Stickler MM, Tran NN, et al. Murinization and H chain isotype matching of the anti-Gitr antibody Dta-1 reduces immunogenicity-mediated anaphylaxis in C57bl/6 mice. J Immunol. 2017;198(11):4502–4512. doi: 10.4049/jimmunol.1601512. PubMed DOI

DiLillo DJ, Ravetch JV. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res. 2015;3(7):704–713. doi: 10.1158/2326-6066.CIR-15-0120. PubMed DOI

Nimmerjahn F, Gordan S, Lux A. Fcgammar dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015;36(6):325–336. doi: 10.1016/j.it.2015.04.005. PubMed DOI

Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79. doi: 10.3389/fimmu.2015.00079. PubMed DOI PMC